Drug Profile
Insulin prandial injectable formulations BIOD 102 and BIOD 103
Alternative Names: BIOD-102; BIOD-103Latest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Biodel
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 18 Nov 2014 Biodel has patent protection for its ultra-rapid-acting insulin formulations in Europe
- 20 Sep 2010 Phase-I clinical trials in Type-1 diabetes mellitus in USA (SC)